Glaxo to Start Late-Stage Trial of Flu Vaccine
From Reuters
British drug company GlaxoSmithKline said it would start a late-stage study of a flu vaccine, the latest effort to help stem the vaccine shortage in the United States.
The vaccine, called Fluarix, is already approved in the U.S. on an emergency basis. This week, health officials agreed to buy as many as 4 million doses of the vaccine.
GlaxoSmithKline said it would begin the 1,000-person trial in four centers in the United States this month.
Separately, Baxter International Inc. said it halted a late-stage European trial of the flu vaccine Preflucel because of higher-than-expected rates of fever and other symptoms.
